| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | BlossomHill Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $257.15M | Series B | 2/29/2024 | $184.15M | $400.87M | $17.63 | Colt Ventures, Cormorant Asset Management, OrbiMed, Vivo Capital, Hercules BioVentures Partners, Plaisance Capital Management, H&D Asset Management, Brahma Capital, Primer Ventures | ||||
 | CytoVale | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $204.3M | Series D | 10/10/2024 | $101M | $333.35M | $2.77 | Sands Capital, CPP Investments, Norwest Venture Partners, Global Health Investment Corporation, Breakout Ventures, Alumni Ventures | ||||
 | Eligible | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $4.36M | Series Seed | 1/13/2015 | $4.36M | $20.68M | $1.41 | Y Combinator, Deerfield Management, RTA Capital, MetaLab | ||||
 | HALO Precision Diagnostics | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $173.71M | Series C-2 | 4/11/2025 | $27.95M | $293.85M | $0.81 | Undisclosed Investors | ||||
 | Ophelia | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $39.71M | Series AA | 3/7/2025 | $15M | $103.93M | $3.09 | Undisclosed Investor | ||||
 | Pendulum Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $121.76M | Series C | 6/30/2023 | $64M | $308.05M | $3.24 | Meritech Capital, Sequoia Capital, True Ventures, Khosla Ventures, Fonterra | ||||
 | Sound Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $25.95M | Series C-2 | 5/24/2018 | $11.76M | $47.84M | $3.00 | Undisclosed Investors | ||||
 | Spinogenix | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $24.4M | Series D | 11/21/2025 | $9.8M | $365.97M | $34.92 | Undisclosed Investors | ||||
 | VideaHealth | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $70.96M | Series B-1 | 1/28/2025 | $40M | $385.89M | $20.34 | Emily Melton, Avenir, BAM Corner Point, Spark Capital, Zetta Venture Partners, Pillar VC | ||||
 | Antares Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $179.72M | Series A-2 | 6/10/2025 | $139.29M | $289.7M | $1.00 | Omega Funds, Atlas Venture, Lightspeed Venture Partners, BVF Partners, Cormorant Asset Management, Vinyanshu Ventures, Abingworth, Invus, Tenmile, Vida Ventures, Willett Advisors | ||||
 | Antheia | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $194.29M | Series C-1 | 6/3/2025 | $73.99M | $160.77M | $0.84 | Global Health Investment Corporation, ATHOS KG, Federov, Viking Global, Sherpalo Ventures, S-Cubed Capital, In-Q-Tel, Civilization Ventures, America's Frontier Fund | ||||
 | Attralus | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $344M | Series B | 2/6/2024 | $172.6M | $428.81M | $7.76 | Logos Capital, Janus Henderson Investors, Redmile Group, Samsara BioCapital, Sarissa Capital Management, Surveyor Capital, Vivo Capital, venBio Partners, Alpha Wave Ventures, Bristol Myers Squibb | ||||
 | Blackrock Neurotech | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $235.02M | Series B-1 | 4/29/2024 | $186.67M | $350M | $0.60 | Tether | ||||
 | Circle Pharma | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $348.74M | Series E-1 | 8/6/2026 | $92.5M | $269.89M | $0.27 | Undisclosed Investors | ||||
 | DispatchHealth | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $315.45M | Series A-1 | 4/30/2026 | $61.99M | $444.87M | $63.16 | Undisclosed Investors | ||||
 | Emulate | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $205.31M | Series F-1 | 3/8/2024 | $54.02M | $132.81M | $1.17 | Undisclosed Investors | ||||
 | Exo | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $43.94M | Series D | 5/28/2025 | $22.09M | $272.82M | $0.86 | Samsung, Sands Capital, Bold Capital, Qubit Health Capital | ||||
 | Neocis | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $163.37M | Series 1-D | 1/10/2024 | $109.61M | $281.57M | $8.66 | DFJ Growth, Vivo Capital, Mithril Capital Management, Norwest Venture Partners, S32, Fred Moll, Intuitive Ventures, Mirae Asset Capital, Mirae Asset Venture Investment, NVIDIA, Courtney Ventures, Florida Opportunity Fund | ||||
 | Numerion Labs | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $132.26M | Series D | 3/10/2026 | $19.79M | $122.5M | $0.37 | Undisclosed Investors | ||||
 | Santa Ana Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $168.34M | Series B-2 | 6/13/2024 | $62.5M | $264.43M | $1.50 | Versant Ventures, TPG, GV, Access Biotechnology, Andreessen Horowitz, RTW Investments | ||||
 | Secretome Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $57.53M | Series A | 5/27/2026 | $30.5M | $231.7M | $2.29 | RA Capital | ||||
 | Vedanta Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $126.86M | Series B-1 | 8/6/2026 | $22.57M | $113.87M | $0.17 | AMR Action Fund, BNP Paribas | ||||
 | Vizgen | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $291.78M | Series E-1 | 1/8/2026 | $41.95M | $171.95M | $0.12 | ARCH Venture Partners, M Ventures, Northpond Ventures | ||||
 | Affinia Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $219.17M | Series C | 10/7/2025 | $40M | $156.61M | $1.62 | New Enterprise Associates, Eli Lilly, Alexandria Venture Investments, Atlas Venture, Avidity Partners, F-Prime Capital, GV, Mass General Brigham Ventures, Perceptive Advisors | ||||